# EDGAR Filing Document

**Accession Number:** 0000010456
**File Stem:** 0001062993-23-003681
**Filing Date:** 2023-2
**Character Count:** 9730
**Document Hash:** a870f76a2ebecf6a6ea7832db8d340ff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-003681.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001062993-23-003681

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230213

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ALMEIDA JOSE E
- **CENTRAL INDEX KEY:** 0001216761

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-04448
- **FILM NUMBER:** 23636235

**MAIL ADDRESS:**
- **STREET 1:** ONE BAXTER PARKWAY
- **CITY:** DEERFIELD
- **STATE:** IL
- **ZIP:** 60015
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BAXTER INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0000010456
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 360781620
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BAXTER PKWY
- **STREET 2:** DF2-1W
- **CITY:** DEERFIELD
- **STATE:** IL
- **ZIP:** 60015
- **BUSINESS PHONE:** 8479482000

**MAIL ADDRESS:**
- **STREET 1:** ONE BAXTER PARKWAY
- **STREET 2:** DF2-1W
- **CITY:** DEERFIELD
- **STATE:** IL
- **ZIP:** 60015

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BAXTER TRAVENOL LABORATORIES INC
- **DATE OF NAME CHANGE:** 19880522

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BAXTER LABORATORIES INC
- **DATE OF NAME CHANGE:** 19760608

## Ex-24

```

POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and
appoints each of David S. Rosenbloom, Ellen K. Bradford and Matthew Rice
signing singly, the undersigned's true and lawful attorney in fact to:
       (1)  execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or director of Baxter
International Inc., or any of its direct or indirect subsidiaries (Baxter)
Forms 4 and 5 in accordance with Section 16(a) of the Securities
Exchange Act of 1934 and the rules thereunder and Form 144 under
Rule 144 under the Securities Act of 1933;
       (2)  do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute
any such Form 4, 5, or 144 and complete and execute any amendment or
amendments thereto, and timely file any such form with the United States
Securities and Exchange Commission and any stock exchange or similar
authority; and
        (3)  take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney in fact, may
be of benefit to, in the best interest of, or legally required by, the
undersigned, it being understood that the documents executed by such
attorney in fact on behalf of the undersigned pursuant to this Power of
Attorney shall be in such form and shall contain such terms and
conditions as such attorney in fact may approve in such attorney in
fact's discretion.
The undersigned hereby grants to each such attorney in fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do if personally present,
with full power of substitution or revocation, hereby ratifying and
confirming all that such attorney in fact, or such attorney in fact's
substitute or substitutes, shall lawfully do or cause or have caused
to be done by virtue of this power of attorney and the rights and
powers herein granted. The undersigned acknowledges that the foregoing
attorneys in fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is Baxter assuming, any of the
undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934 and Rule 144 of the Securities Act
of 1933.
This Power of Attorney shall super cede any power of attorney
previously granted by the undersigned with respect to the subject
matter herein and shall remain in full force and effect until the
undersigned is no longer required to file Forms 4, 5 and 144 with
respect to the undersigned's holdings of, and transactions in,
securities issued by Baxter, unless earlier revoked by the
undersigned in a signed document delivered to Baxter.

       IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 16th day of May, 2022.

/s/ Jose E. Almeida

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ALMEIDA JOSE E<br><sub>(Last) (First) (Middle)</sub><br>ONE BAXTER PARKWAY<br><sub>(Street)</sub><br>DEERFIELD, IL 60015<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-13 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chairman, CEO and President_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BAXTER INTERNATIONAL INC [ BAX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock, $1 par value | 2023-02-13 |  | A |  | 31044<sup>(1)</sup> | A | $0 | 355265 | D |  |
| Common Stock, $1 par value | 2023-02-13 |  | F |  | 10053<sup>(2)</sup> | D | $40.50 | 345212 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Represents shares awarded from the performance share unit award granted on March 20, 2020 pursuant to the Equity Plan adopted by Baxter International Inc. (Baxter) as of such date (the 2020 PSUs).  The award provided that one-third of the performance share units are awarded based on Baxter's Sales Compound Annual Growth Rate (Sales CAGR) performance, Baxter's Total Shareholder Return (TSR) performance, and Baxter's Total Return on Invested Capital (ROIC) performance over the three-year performance period January 1, 2020 to December 31, 2022 (the Three-Year Performance Period). These shares have vested as the Three-Year Performance Period has ended.

(2) Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of the 2020 PSUs.

**Signature:** /s/ Matthew Rice, as attorney in-fact for Jose E. Almeida  
**Date:** 2023-02-15

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**